Skip to main
TDOC
TDOC logo

Teladoc (TDOC) Stock Forecast & Price Target

Teladoc (TDOC) Analyst Ratings

Based on 36 analyst ratings
Hold
Strong Buy 17%
Buy 25%
Hold 56%
Sell 0%
Strong Sell 3%

Bulls say

Teladoc Health Inc. has demonstrated resilience as evidenced by BetterHelp's sequential membership growth after five consecutive declines, alongside the Integrated Care segment onboarding 800 new clients in January. The company also reported a year-over-year increase of 4% in Chronic Care program enrollments, totaling 1.203 million, which signifies a solid demand for its services. Moreover, the fourth-quarter GAAP EPS was significantly improved due to effective expense management, highlighting Teladoc's potential for future growth within the expanding virtual care market.

Bears say

Teladoc Health Inc. is facing a challenging financial outlook, with total revenue declining by 3.0% year-over-year, primarily driven by a significant contraction of 9.5% in its BetterHelp segment. While the Integrated Care segment experienced modest growth of 1.6%, the persistent decline in users for BetterHelp over five consecutive quarters raises concerns about future performance. Furthermore, the company has indicated that its profitability outlook is negatively impacted by the Catapult acquisition, compounding worries about sustained revenue growth and operational efficiency.

Teladoc (TDOC) has been analyzed by 36 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 25% recommend Buy, 56% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teladoc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teladoc (TDOC) Forecast

Analysts have given Teladoc (TDOC) a Hold based on their latest research and market trends.

According to 36 analysts, Teladoc (TDOC) has a Hold consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teladoc (TDOC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.